Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

• Published in: Journal of primary care & community health Vol. 15; p. 21501319241259905
• Main Authors: Rastogi, Anjay, Collins, Ashté, Kelepouris, Ellie, Kotzker, Wayne, Middleton, John P, Rajpal, Minesh, Roy-Chaudhury, Prabir, Chertow, Glenn M
• Format: Journal Article
• Language: English
• Published: United States SAGE Publishing 01-01-2024
• Subjects: Cardiovascular Diseases - prevention & control; Humans; Nephrologists; Practice Guidelines as Topic; Renal Insufficiency, Chronic - drug therapy; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; consensus; KDIGO; treatment algorithm; chronic kidney disease; SGLT2 inhibitor
• ISSN: 2150-1327; 2150-1327
• DOI: 10.1177/21501319241259905

There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co-transporter-2 (SGLT2) inhibitor use in patients with CKD, focusing on practical considerations. Initially developed as glucose-lowering drugs, SGLT2 inhibitors preserve kidney function and reduce risks of cardiovascular events and mortality. Clinical benefits of SGLT2 inhibitors in CKD have been demonstrated in multiple clinical trials, yet utilization in practice remains relatively low, likely due to the complexity of labeled indications (past and present) and misconceptions about SGLT2 inhibitors as a class.
A panel of 8 US-based nephrologists convened in August 2022 to develop consensus guidance for the primary care community surrounding risk assessment as well as initiation and implementation of SGLT2 inhibitors in patients with CKD. Here, we provide an adapted version of the Kidney Disease: Improving Global Outcomes (KDIGO) heatmap and a treatment-decision algorithm.
We advocate SGLT2 inhibitors as co-first-line therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors, where RAAS inhibitor dose titration need not be completed before initiation of an SGLT2 inhibitor. In fact, SGLT2 inhibitor therapy may facilitate up-titration or maintenance of optimal RAAS inhibitor dosing. We describe potential strategies to aid implementation of an SGLT2 inhibitor in clinical practice, including improving education and awareness among care providers and patients and dispelling misconceptions about the safety of SGLT2 inhibitors. In summary, we support the use of SGLT2 inhibitors with RAAS inhibitors as co-first-line therapy in most patients with CKD.